Abstract: Process for the preparation of motilin-like polypeptide, a recombinant DNA therefor, and a plasmid, in which the recombinant DNA is inserted.

Abstract: A method of enzymatically measuring hydrogen peroxide by developing a color with use of 3-methyl-2-benzothiazolinoehydrazone as a coupler and in combination with an oxidative color developing reagent with peroxidase, and a reagent therefor is described. Catalase is added to the 3-methyl-2-benzothiazolinonehydrazone reagent as a stabilizer and the reaction is carried out in the presence of ethylenediaminetetraacetic acid or an analogue thereof. The color developing reaction may be carried out in neutral or weak alkali conditions. A reagent is described which comprises a buffer, 3-methyl-2-benzothiazolinohydrazone, and catalase.

Abstract: A readily absorbable type of motilin preparation containing a motilin-like active substance and a surface active agent is provided, in which the motilin-like active substance is mainly L-leucine-13-motilin-homoserine, and the surface active agent is selected from the group consisting of a bile salt, saponin and a polyethylene glycol higher-alcohol ether for nasal administration purposes and is a peptide lytic enzyme inhibitor for oral administration purposes.

Abstract: There are described a novel protein derived from Clostridium perfringens FERM BP-4584 method of obtaining the same and use thereof as an effective ingredient for treating wounds and ulcers. The protein has a molecular weight of 420,000.+-.40,000 by a GPC, isoelectric point of 4.8, and consists of a single subunit having a molecular weight of 130,000.+-.20,000 by a SDS-polyacrylamide gel electrophoresis, and shows cell growth-stimulating activity as well as macrophage chemotactic action. The protein can be extracted and separated by conventional techniques for obtaining a protein from general microorganisms, by taking an inhibition of decomposition into consideration, since the protein is not so stable.

Abstract: Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group,in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitogen or oxygen atom,--CH.sub.2 OH.sub.3 group or ##STR3## group, in which R.sub.3 and R.sub.

Abstract: There are disclosed a benzo[b]furancarboxamide derivative of the formula ##STR1## wherein R.sup.a, R.sup.b, R.sup.c and R.sup.d are a hydrogen atom or lower alkyl group, respectively; R.sup.e is a hydrogen atom, amino radical, lower alkylamino group or acylamino group; X is a hydrogen atom or halogen atom; and n is an integer of 1-5,and including racemic compounds and stereo-isomers thereof, a salt of the compounds, a process for the preparation of the compounds and salts as well as use thereof for improving hypermotility.

Abstract: Early diagnosis of mastitis or garget is carried out by measuring the concentration of 3-hydroxybutyric acid in milk. Used to this end is a reagent reacting with 3-hydroxybutyric acid to show a color at a concentration of 100 .mu.mol/l or higher.

Abstract: A pharmaceutical composition for stimulating peristaltic contraction in the intestinal canal which contains a pharmaceutically acceptable carrier or excipient and an effective amount of a polypeptide, or a salt thereof, having a pharmacological activity similar to motilin. The polypeptide has the formula B.sub.1 -Z.sub.1 -A.sub.1 -Z.sub.2 -B.sub.2 -Thr-B.sub.3 -A.sub.2 -Glu-Z.sub.3 -C-Arg-X'-Gln-Glu-Lys-Glu-Arg-D-Lys-Gly-E-Y, with Z.sub.1,Z.sub.2 and Z.sub.3 each being an amino acid residue having a hydrophobic side-chain, A.sub.1 and A.sub.2 each being an amino acid residue such as Pro, Gly, Asn and Ser, B.sub.1, B.sub.2 and B.sub.

Abstract: There is disclosed a pharmaceutical preparation which contains vasoactive intestinal polypeptide (VIP), its analogue or a salt thereof, and a surfactant. The preparation shall contains further a peptidase inhibitor. The composition is administrated to suppress allergies, reduce blood pressure, increase secretion of tear, cure asthma and impotence and others.

Abstract: A process for separating and recovering serum and plasma components from a whole blood sample including passing a whole blood sample through a separating filter formed of a blood cell separating layer composed mainly of fibers impregnated with a coating agent. A device includes a blood collector having a needle at one end and a blood suction means at the other end, and a separating filter including a blood cell separating layer, the filter being provided in the intermediate zone of the blood collector, whereby a whole blood sample sucked through the needle by depressurizing the blood suction means is passed through the separating filter.

Abstract: The invention provides a novel glycoside which contains as the aglycon a 4-(substituted phenyl)piperazine-1-yl derivative of glycyrrhetinic acid and 11-deoxo-glycyrrhetinic acid or their derivative as well as a composition for the treatment of virus infection, which contains these compounds as a main active component.

Abstract: A composition comprising an organogermanium compound represented by the formula ##STR1## wherein n is an integer of 1 or more, R is hydrogen, alkyl, --COOH, --COOR', phenyl, ##STR2## and R' is a lower alkyl and a high molecular carrier, as well as an immunity adjusting agent comprising the composition. The treatment of hepatitis with compositions containing this germanium derivative.

Abstract: A composition comprising an organogermanium compound represented by the formula ##STR1## wherein n is an integer of 1 or more, R is hydrogen, alkyl, --COOH, --COOR', phenyl, ##STR2## and R' is a lower alkyl and a high molecular carrier, as well as an immunity adjusting agent comprising the composition.

Abstract: There is disclosed a pharmaceutical composition of stabilized [Leu.sup.13 ]-motilin-Hse. The composition comprises at least one of organic acids and salts thereof, as a first stabilizer, and pH thereof is adjusted in a range of 5.5-8.0. The composition may contain at least one of substances selected from saccharides, amino acids, proteins and salts thereof, as a second stabilizer. Conversion of [Leu.sup.13 ]-motilin-Hse into [Leu.sup.13 ]-motilin-Hse-lactone is suppressed by increasing pH value and deamidization in asparagine residue at 19-position is suppressed by the presence of the organic acid or salt thereof.

Abstract: Even when the specimen contains human granulocyte elastase in the form of a mixture of free elastase with an elastase-inhibitor complex or complexes, the present invention enables the total quantity of elastase in that specimen to be precisely detected. The inhibitor is added to free elastase to convert it into an elastase-inhibitor complex, whereby the quantity of elastase can be measured by immunoassay as the total amount including the previously existing elastase-inhibitor complex. It is possible to precisely measure the total amount of elastase in mucus collected from the cervical canal of a pregnant woman, sputum or a rinsed solution of bronchovesicular lavage in which free elastase is mixed with an elastase-inhibitor complex.

Abstract: A 3-oxygermylpropionic acid preparation is provided, which activates the action of 3-oxygermylpropionic acid having the general formula:[(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH]n wherein n=an integer of at least 1 and is readily solubilized and disintegrated in vivo. The present preparation is manufactured by compression-molding at high pressure a composition comprising 3-oxygermylpropionic acid and two or more low-molecular substance of high solubility in water. The low-molecular substances are selected from the group consisting of white sugar, sorbitol, fructose, sucrose, glucose, lactose, mannitol and sodium chloride.

Abstract: A percutaneous-administration-type pharmaceutical preparation of nitroglycerin is provided. The preparation comprises a backing that is impervious to medicines, and a pressure-sensitive adhesive layer that is placed on one surface of said backing, wherein said pressure-sensitive adhesive layer contains an alkyl (meth)acrylate (co)polymer in the concentration of 35-85% by weight, nitroglycerin in the concentration of 10-30% by weight, and a silicic acid anhydride in the concentration of 5-20% by weight, said (co)polymer contains as major (co)polymer components alkyl (meth)acrylates with alkyl groups having 6 or more carbon atoms, which alkyl (meth)acrylates include 2-ethylhexyl methacrylate in the concentration of 40-100% by weight based on the total weight of said alkyl (meth)acrylates. The preparation makes it possible for nitroglycerin to be absorbed percutaneously at a controlled rate for a long period of time. Also, even a compact preparation can supply a sufficient amount of nitroglycerin.

Abstract: An organic germanium compound to be effectively used for curing AIDS or making AIDS asymtomatic in various forms is expressed by the following rational formula: ##STR1## wherein n is an integer of 1 or 2 or more, is in the form of a white acicular or needle crystal, shows a solubility of 1.570/100 ml in water at 25.degree. C. and exhibits a melting (decomposition) point of 240.degree. C.

Abstract: A composition for inhibiting the degeneration of cells including liver cells by drugs and relieving the toxicity of drugs to internal organs including the liver contains as an essential component a 3-oxygermylpropionic acid polymer which is represented by:[(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH].sub.nwherein n is an integer of at least 1, takes the form of a white acicular crystal and has a melting point of about 230.degree. C. at which it decomposes or coagulates. The present composition may be used with a carrier hydroxypropylcellulose in an amount of 0.005 to 50% by weight relative to 0.005 to 5% by weight of the 3-oxygermylpropionic acid polymer.

Abstract: Pharmaceutical compositions for oral administration used for the treatment and prevention of hyperlipemia, obesity and obesity-related diseases contain phytic acid or its salt as a pharmaceutically effective component.